TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06961383: Study of NG01 Cell Therapy in Secondary Progressive Multiple Sclerosis

Sponsor: NeuroGenesis Ltd. · Phase: PHASE2 · Area: CNS_NEUROLOGY · Target Enrollment: 45 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$12,416,000

Rescue Site Savings

+$8,186,800

Unlock Full NCT06961383 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06961383 Rescue Dossier →